<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00077688</url>
  </required_header>
  <id_info>
    <org_study_id>SON-8184-1073</org_study_id>
    <nct_id>NCT00077688</nct_id>
  </id_info>
  <brief_title>TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium</brief_title>
  <official_title>A Phase 2 Multicenter Evaluation of the Safety and Efficacy of TOCOSOL(TM) Paclitaxel (S-8184 Paclitaxel Injectable Emulsion) in Patients With Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma of the Urothelium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achieve Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Achieve Life Sciences</source>
  <brief_summary>
    <textblock>
      Phase 2B, multicenter study evaluating the safety and efficacy of weekly TOCOSOL Paclitaxel&#xD;
      in taxane-naive patients receiving second line chemotherapy for metastatic or locally&#xD;
      advanced, unresectable transitional cell carcinoma of the urothelium&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 2 years</measure>
  </secondary_outcome>
  <enrollment>44</enrollment>
  <condition>Bladder Neoplasms</condition>
  <condition>Ureteral Neoplasms</condition>
  <condition>Urethral Neoplasms</condition>
  <condition>Carcinoma, Transitional Cell</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOCOSOL Paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic diagnosis of transitional cell carcinoma (TCC) of the urothelium including&#xD;
             bladder, renal pelvis, ureter, or urethra&#xD;
&#xD;
          -  Stage IV disease&#xD;
&#xD;
          -  One and only one prior systemic cytotoxic chemotherapy regimen administered as&#xD;
             adjuvant or neoadjuvant chemotherapy or to treat locally advanced or metastatic&#xD;
             disease&#xD;
&#xD;
          -  Adequate hematologic function (ANC &gt;/= 1500 cells/mm3 &amp; platelet count &gt;/=&#xD;
             100,000/mm3)&#xD;
&#xD;
          -  Serum creatinine &lt;/= 2.0 mg/dL&#xD;
&#xD;
          -  Total bilirubin &lt;/= 1.5 mg/dL&#xD;
&#xD;
          -  SGOT &amp; SGPT &lt;/= 3 times upper limit of institutional normal values&#xD;
&#xD;
          -  PT (INR) &amp; PTT within institutional lab normal range&#xD;
&#xD;
          -  Karnofsky performance status of 60-100%&#xD;
&#xD;
          -  At least one unidimensionally measurable lesion, suitable for radiographic evaluation&#xD;
             of disease response, consistent with RECIST criteria&#xD;
&#xD;
          -  Signed IRB/EC approved Informed Consent&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Fully recovered from any previous surgery&#xD;
&#xD;
          -  Not pregnant and willing to use a medically effective form of contraception during&#xD;
             periods of chemotherapy treatment (both males and and females)&#xD;
&#xD;
          -  Agree not to take vitamin E supplementation while receiving study medication&#xD;
&#xD;
          -  Willing to participate in requested follow-up evaluations&#xD;
&#xD;
          -  Willing to permit treating physicians to provide information to Sonus regarding&#xD;
             disease status and survival for 2 years after first dose of study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior taxane-containing chemotherapy including Taxol(R) (paclitaxel) or generic&#xD;
             equivalent, or Taxotere(R) (docetaxel)&#xD;
&#xD;
          -  Peripheral neuropathy NCI-CTC grade 2 or greater&#xD;
&#xD;
          -  Wide-field radiation, cytotoxic chemotherapy or hormonal therapy within 4 weeks of&#xD;
             first dose, or mitomycin or nitrosoureas within 6 weeks of first dose, of study drug&#xD;
&#xD;
          -  An investigational agent within 4 weeks of first dose of study drug&#xD;
&#xD;
          -  Concurrent anticonvulsants known to induce P450 isoenzymes&#xD;
&#xD;
          -  Patients who are pregnant or lactating&#xD;
&#xD;
          -  A history of carcinoma of another primary site (other than non-melanoma skin cancers&#xD;
             or carcinoma-in-situ of the cervix) within the previous 5 years, unless metastatic&#xD;
             disease has been biopsied and documented to be TCC&#xD;
&#xD;
          -  Bone metastasis, effusions, ascites or elevated tumor markers as the only evidence of&#xD;
             metastatic TCC&#xD;
&#xD;
          -  Brain metastasis&#xD;
&#xD;
          -  Active bowel obstruction&#xD;
&#xD;
          -  Active, serious infection or other serious medical problems (other than TCC) likely to&#xD;
             impair completion of the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Maryland Medical Center/Greenbaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington/Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>February 10, 2004</study_first_submitted>
  <study_first_submitted_qc>February 13, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2004</study_first_posted>
  <last_update_submitted>June 2, 2009</last_update_submitted>
  <last_update_submitted_qc>June 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Ureteral Neoplasms</mesh_term>
    <mesh_term>Urethral Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

